PSMB5 Antibody

What is PSMB5 and what are its alternative names in scientific literature?

PSMB5 (Proteasome subunit beta type-5) is a component of the ubiquitin-proteasome system and belongs to the peptidase T1B family. In scientific literature, it is also known by several alternative names including LMPX, MB1, and X. This protein is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly acidic pH . Understanding these nomenclature variations is essential when conducting literature searches to ensure comprehensive coverage of relevant research findings.

What are the typical applications for PSMB5 antibodies in research?

PSMB5 antibodies are widely utilized in multiple experimental applications including Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF/ICC), and ELISA. These antibodies demonstrate reactivity with human samples and have been cited in studies involving both human and mouse specimens . The versatility of these applications enables researchers to investigate PSMB5 expression, localization, and function across different experimental contexts, from cell culture systems to tissue specimens.

What is the molecular weight of PSMB5 protein and how does this information guide antibody validation?

The calculated molecular weight of PSMB5 is 28 kDa (263 amino acids), although the observed molecular weight in experimental settings is typically around 22 kDa . This discrepancy between theoretical and observed molecular weights is important for researchers to note when validating antibody specificity in Western blot experiments. When bands appear at 22 kDa rather than 28 kDa, this represents the expected pattern for PSMB5 detection rather than an experimental artifact or non-specific binding.

What cell lines have been validated for PSMB5 antibody testing?

PSMB5 antibodies have been successfully validated in several human cell lines including HeLa cells, HepG2 cells, Jurkat cells, and L02 cells for Western blot applications . Additionally, immunofluorescence applications have been validated in HeLa cells, BAEC cells, and A431 cells . This information guides researchers in selecting appropriate positive control cell lines when establishing PSMB5 detection protocols in their specific experimental systems.

How should researchers optimize PSMB5 antibody dilutions for different experimental applications?

The optimal dilution of PSMB5 antibody varies by application type and specific experimental conditions. Based on validated protocols, the following dilution ranges are recommended:

It is crucial to note that these ranges serve as starting points, and researchers should perform titration experiments within these ranges to determine the optimal antibody concentration for their specific experimental system . The optimal dilution may vary depending on the specific tissue or cell type being examined, fixation methods, and detection systems employed.

What antigen retrieval methods are most effective for PSMB5 immunohistochemistry?

For immunohistochemical detection of PSMB5 in formalin-fixed, paraffin-embedded tissues, the recommended antigen retrieval approach is using TE buffer at pH 9.0. As an alternative method, citrate buffer at pH 6.0 can also be employed . The choice between these two retrieval methods may depend on the specific tissue being examined and the fixation protocol used. Researchers should perform comparative studies with both retrieval methods on their specific samples to determine which provides optimal signal-to-noise ratio and preservation of tissue morphology.

What are the recommended protocols for immunofluorescent detection of PSMB5?

For immunofluorescence applications, validated protocols include:

• Fixation: Formalin fixation

• Permeabilization: 0.1% Triton X-100 in TBS for 5-10 minutes

• Antibody dilution: 1:100

• Incubation: Overnight at 4°C

This protocol has been successfully validated in multiple cell lines including HeLa, BAEC, and A431 cells . For visualization, primary antibody detection appears as green fluorescence, while nuclei are counterstained blue and actin filaments red, providing clear subcellular localization information for PSMB5 protein.

How can researchers verify PSMB5 antibody knockdown efficiency in experimental models?

To verify the knockdown efficiency of PSMB5-targeting shRNA, researchers can employ co-transfection experiments with HA-tagged PSMB5 plasmids. Significant reduction in exogenous HA-PSMB5 protein expression following co-transfection with shPSMB5 plasmid confirms functional knockdown capability. For endogenous PSMB5 verification, transfection of cells like THP-1 with shPSMB5 should produce measurable decreases in PSMB5 protein levels as detected by Western blot . This dual verification approach (exogenous tagged protein and endogenous protein) provides comprehensive validation of knockdown efficiency.

What evidence supports PSMB5 as a potential therapeutic target in cancer?

Multiple lines of evidence support PSMB5 as a promising therapeutic target in cancer:

• Bioinformatics analysis of breast cancer databases (TCGA and METABRIC) demonstrates that PSMB5 is overexpressed in breast cancer tissues compared to normal tissues

• High PSMB5 expression correlates with worse survival outcomes in breast cancer patients

• CCLE analysis confirms that PSMB5 is distinctively upregulated in breast cancer cell lines

• Functional experiments show that PSMB5 knockdown inhibits cancer cell growth and migration

• PSMB5 knockdown in vivo significantly decreases tumor growth in a subcutaneous mouse model

These findings collectively indicate that PSMB5 exhibits oncogenic properties and represents a potential therapeutic target in breast cancer treatment strategies.

How does PSMB5 influence the tumor microenvironment and immune response?

PSMB5 plays a dual role in the tumor microenvironment by affecting both cancer cells and immune cells:

• In cancer cells: PSMB5 promotes growth and migration, contributing to tumor progression

• In immune cells: PSMB5 is highly expressed in M2 macrophages (immunosuppressive phenotype)

• Knockdown of PSMB5 promotes the differentiation of monocytes into M1 macrophages (pro-inflammatory, anti-tumor phenotype)

• M1 macrophage markers including MCP-1 and IL-1β are increased following PSMB5 knockdown

This dual role makes PSMB5 particularly interesting as a therapeutic target that could simultaneously inhibit tumor growth while enhancing anti-tumor immune responses. The ability to modify the tumor microenvironment by alleviating immunosuppressive effects represents a promising strategy for cancer immunotherapy.

What experimental models are most appropriate for studying PSMB5 in cancer research?

Based on the research findings, several experimental models have been validated for studying PSMB5 in cancer contexts:

• In vitro cellular models:

  • THP-1 monocyte/macrophage system for immune cell studies

  • MDA-MB-231 breast cancer cells for tumor cell growth and migration studies

  • Colony formation assays and Boyden chamber assays for functional studies

• In vivo models:

  • Subcutaneous mouse xenograft models with lentiviral delivery of PSMB5 shRNA

These models provide complementary approaches to investigate the dual oncogenic and immunosuppressive roles of PSMB5, allowing researchers to examine both tumor cell-intrinsic effects and interactions with the immune microenvironment.

What are the primary considerations for PSMB5 antibody storage and handling?

PSMB5 antibodies should be stored at -20°C, where they remain stable for one year after shipment. The storage buffer typically consists of PBS with 0.02% sodium azide and 50% glycerol at pH 7.3. Notably, aliquoting is unnecessary for -20°C storage, which simplifies laboratory handling procedures. Some preparations (20μl sizes) contain 0.1% BSA as a stabilizing agent . When working with these antibodies, researchers should avoid repeated freeze-thaw cycles and maintain sterile handling techniques to preserve antibody functionality and specificity.

How can researchers address inconsistent PSMB5 signal intensity in Western blot applications?

Inconsistent signal intensity in Western blot applications can result from several factors. To address this issue, researchers should:

• Verify protein loading consistency using housekeeping proteins

• Ensure complete protein transfer to the membrane

• Optimize primary antibody concentration (testing the 1:500-1:2000 range)

• Extend primary antibody incubation time (overnight at 4°C often yields better results)

• Consider the effect of detergents in lysis buffers on PSMB5 protein extraction efficiency

• Test different blocking agents if background issues occur

Additionally, researchers should note that PSMB5 expression levels may genuinely vary across different cell types and experimental conditions, particularly in cancer cell lines where expression is elevated compared to normal cells .

What controls should be included when using PSMB5 antibodies in functional studies?

For rigorous experimental design when using PSMB5 antibodies in functional studies, researchers should include:

• Positive controls:

  • HeLa, HepG2, Jurkat, or L02 cells for Western blot applications

  • Human breast cancer tissue for IHC applications

• Negative controls:

  • Primary antibody omission controls for all applications

  • Isotype-matched irrelevant antibody controls

  • PSMB5 knockdown cells (using validated shRNA constructs)

• Validation controls:

  • When studying PSMB5 knockdown effects, both exogenous (HA-tagged) and endogenous PSMB5 knockdown efficiency should be confirmed

  • For M1/M2 macrophage studies, PMA treatment (320 nM for 6 hours) followed by PMA plus LPS (100 ng/ml) and IFN-γ (20 ng/ml) for 24 hours serves as a positive control for M1 polarization

How might PSMB5 targeting be incorporated into cancer immunotherapy strategies?

Based on the dual role of PSMB5 in cancer development, integrating PSMB5 targeting into cancer immunotherapy represents a promising approach. Strategic considerations include:

• Development of specific PSMB5 inhibitors that simultaneously affect cancer cells and immune cells

• Combination therapies that pair PSMB5 inhibition with existing immunotherapies (checkpoint inhibitors)

• Investigation of delivery systems that can selectively target PSMB5 in both tumor cells and tumor-associated macrophages

• Exploration of biomarkers to identify patients most likely to benefit from PSMB5-targeting approaches

The unique ability of PSMB5 inhibition to both attenuate tumor-cell growth and modify the tumor microenvironment by activating M1 macrophages could potentiate the efficacy of current immunotherapeutic strategies . Future research should focus on optimizing delivery methods for PSMB5-targeting agents and identifying synergistic therapeutic combinations.

What are the emerging methods for studying PSMB5 function beyond traditional antibody applications?

Beyond traditional antibody-based detection methods, emerging approaches for studying PSMB5 function include:

• CRISPR/Cas9-based gene editing for precise manipulation of PSMB5 expression

• Single-cell analysis techniques to explore heterogeneity in PSMB5 expression within tumor microenvironments

• Patient-derived organoid models to assess PSMB5 targeting in more physiologically relevant systems

• Computational approaches integrating multi-omics data to predict PSMB5 regulatory networks

• Development of small molecule inhibitors specific to PSMB5 for pharmacological studies

These advanced methodologies complement traditional antibody applications and can provide deeper insights into the mechanistic roles of PSMB5 in cancer biology and immune regulation. The integration of these approaches with conventional antibody-based methods will enable more comprehensive understanding of PSMB5 biology.

How does PSMB5 expression correlate with response to proteasome inhibitors in clinical settings?

While the provided search results don't directly address correlations between PSMB5 expression and clinical response to proteasome inhibitors, this represents an important area for future investigation. Researchers should consider:

• Analyzing PSMB5 expression levels in patient samples before and after treatment with proteasome inhibitors

• Investigating whether PSMB5 mutations or polymorphisms predict resistance to proteasome inhibitors

• Examining how changes in PSMB5 expression correlate with clinical outcomes in patients receiving proteasome inhibitor therapy

• Developing companion diagnostic tests based on PSMB5 expression to guide treatment decisions